Nuvectis Pharma
Sector: Healthcare & Life Sciences
About Nuvectis Pharma
Biopharmaceutical company focused on the development of innovative precision medicines for the treatment of cancer. (NASDAQ: NVCT)
Products
NXP800 (HSF1 Inhibitor); NXP900 (SRC/YES1 Inhibitor)
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action (Type 1.5 inhibitor) which results in inhibition of both the catalytic and scaffolding functions of the SRC kinase, thereby providing a complete shutdown of the signaling pathway. NXP900 completed a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers, supporting the phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents